Since 1990, the ADC at NYU has been providing core resources and support to a comprehensive, multidisciplinary research program on aging and AD that spans basic through psychosocial research. The main scientific goal of the ADC is to facilitate and enhance research that will lead to early diagnosis and prevention. Over the next 5-years, core resources will be used to study the transition from normal aging to mild cognitive impairment (MCI) and early AD. In addition to NYU SoM, investigators at the Nathan Kline Institute (NKI), the NYS Institute for Basic Research (IBR), and other New York City area facilities are also participating. Patients with AD and related disorders, subjects with MCI, and cognitively normal subjects are studied longitudinally through postmortem. A Director and Associate Leaders who serve on an Executive Committee and an External Advisory Committee supervise the ADC. Standard ADC cores supported consist of Administrative, Clinical, Neuropathology, Data Management and Education Cores. In addition, Neuroimaging and Caregiver Cores significantly strengthen the research contributions of ADC investigators. The Clinical Core includes a Satellite Multicultural Program focusing on minority recruitment, and an ADC Biorepository (a joint effort of the Clinical, Neuroimaging and Neuropathology Cores) stores and provides investigators with CSF, blood and postmortem brain tissue samples. The Neuropathology Core includes a morphometry component at IBR. Each year, the ADC directly supports several pilot studies, and provides core resources (subjects;clinical, neuroimaging and psychosocial data;blood, CSF and brain tissue) to extensive current research receiving primary support from NIH and other sources. The extensive multidisciplinary research utilizing the ADC has been strengthened by the creation of a Center of Excellence on Brain Aging. There is also extensive collaboration with other ADC's and national consortia, and data from the NYU ADC is shared with the National Alzheimer's Coordinating Center (NACC) and with numerous collaborating investigators. The ADC has made and will continue to make substantial contributions toward eliminating the problem of AD.

Public Health Relevance

There are more than 5-million AD patients in the U.S, a number that will triple in the next few decades due to the dramatic expansion of the elderly population. This neurodegenerative disease has a devastating impact on patients and families and on the healthcare system. In supporting research on early detection and prevention, the ADC will help reduce and eventually eliminate this major public health problem.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG008051-25
Application #
8672568
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J1))
Program Officer
Silverberg, Nina B
Project Start
1997-07-15
Project End
2015-04-30
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
25
Fiscal Year
2014
Total Cost
$1,828,568
Indirect Cost
$690,006
Name
New York University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
John, Samantha E; Gurnani, Ashita S; Bussell, Cara et al. (2016) The effectiveness and unique contribution of neuropsychological tests and the δ latent phenotype in the differential diagnosis of dementia in the uniform data set. Neuropsychology 30:946-960
Bonham, Luke W; Geier, Ethan G; Fan, Chun C et al. (2016) Age-dependent effects of APOE ε4 in preclinical Alzheimer's disease. Ann Clin Transl Neurol 3:668-77
Brown, Ryan; Lakshmanan, Karthik; Madelin, Guillaume et al. (2016) A nested phosphorus and proton coil array for brain magnetic resonance imaging and spectroscopy. Neuroimage 124:602-11
Ting, Simon Kang Seng; Hao, Ying; Chia, Pei Shi et al. (2016) Clinicopathological correlation of psychosis and brain vascular changes in Alzheimer's disease. Sci Rep 6:20858
Fischer, Corinne E; Qian, Winnie; Schweizer, Tom A et al. (2016) Lewy Bodies, Vascular Risk Factors, and Subcortical Arteriosclerotic Leukoencephalopathy, but not Alzheimer Pathology, are Associated with Development of Psychosis in Alzheimer's Disease. J Alzheimers Dis 50:283-95
Karch, Celeste M; Ezerskiy, Lubov A; Bertelsen, Sarah et al. (2016) Alzheimer's Disease Risk Polymorphisms Regulate Gene Expression in the ZCWPW1 and the CELF1 Loci. PLoS One 11:e0148717
McCutcheon, Sarah T; Han, Dingfen; Troncoso, Juan et al. (2016) Clinicopathological correlates of depression in early Alzheimer's disease in the NACC. Int J Geriatr Psychiatry 31:1301-1311
Tosto, Giuseppe; Monsell, Sarah E; Hawes, Stephen E et al. (2016) Progression of Extrapyramidal Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates. J Alzheimers Dis 49:1085-93
Wisniewski, Thomas; Drummond, Eleanor (2016) Developing therapeutic vaccines against Alzheimer's disease. Expert Rev Vaccines 15:401-15
Chapman, Kimberly R; Bing-Canar, Hanaan; Alosco, Michael L et al. (2016) Mini Mental State Examination and Logical Memory scores for entry into Alzheimer's disease trials. Alzheimers Res Ther 8:9

Showing the most recent 10 out of 444 publications